R-nuucell is focused on the synthesis of new metallodrugs based on robust metal-based scaffolds to generate new libraries of compounds, screened against a panel of human cancer cell lines.

The anticancer potential of the new metallodrugs is evaluated by several chemical, biochemical and biological studies, both in vitro and in vivo.


Development phase
Nonclinical Trials
Clinical Trials
Triple negative breast cancer
Colorectal cancer
Non-small lung cancer


Synthesis & Analytical Chemistry
R-nuucell has accessible a set of instrumentation and equipment to support the synthesis, purification and full characterization of our new metallodrugs.
Drug Screening
All drugs are tested in vitro against a wide panel of several human cancer cell lines with different genetic alterations and degrees of aggressiveness and in healthy human cell lines.
Lead Compound Optimization
The most promising structures are selected based on their cytotoxicity, selectivity, mode of action, identified targets, among others. Formulation studies to allow for in vivo administration are performed.
IP Protection
Our new drugs technology is patented (active drug + targeted disease).
In Vivo Proof-of-Concept
The hit compounds are tested in in vivo models for toxicity and activity in our laboratories.
Pre-Clinical Studies Validation
The selected compounds are tested in accredited laboratories thorough detailed in vitro, ex vivo and in vivo efficacy, toxicity and pharmacokinetics assays.
© 2023 R-nuucell. All rights reserved. Website by João Vitorino